The HIMALAYA Study: STRIDE for uHCC Shows Beneficial 5-Year OS Results

Lorenza Rimassa, MD, of Humanitas University, gives an overview of the phase 3 HIMALAYA study and its 5-year overall survival results that were presented at ESMO Congress 2024.

The study examined tremelimumab plus durvalumab for the treatment of unresectable hepatocellular carcinoma, and found the combination to significantly improve overall survival over sorafenib alone.